Cantor Fitzgerald analyst Bryan Brokmeier initiated Thermo Fisher with an Overweight rating, as he sees significant opportunity for organic growth and for M&A. He set a $194 price target on Thermo Fisher, which he calls a "key beneficiary" of continued strength in biopharma.
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here